It is no surprise to anyone in the medical device industry that the transition from EU MDD to EU MDR has seen quite a few hiccups over the past couple of years. The most recent obstacle, however, comes in the form of delays from Notified Bodies. The scale of the bottleneck coming from Notified Body capacity to review EU MDR applications has not been a secret, but a recent industry poll sheds light on the growing concern.

In April of this year, the Medical Device Coordination Group (MDCG) task forced polled industry members to better understand how limited Notified Body capacity was affecting them. According to the poll, nearly 85% of products previously certified under MDD are still awaiting MDR review by Notified Bodies. This accounts for nearly 500,000 devices that were previously on the European Market under MDD and are actively awaiting MDR review.[1]

These are staggering figures that shine a hard-to-miss spotlight on some of the major downfalls of the rocky transition. These issues are major concerns for larger companies but are potentially disastrous for smaller to medium-sized companies attempting to gain a foothold in the EU market. Considering some of these challenges, some companies have decided to pull their products from the EU market altogether by reducing product portfolios for European customers. This, in turn, could mean a reduction in accessible medical treatments for patients.

The bottleneck in the review phase is equating to an average 13–18-month MDR certification, which only heightens to criticality for medical device manufacturers to get started ASAP on their transition and final application submission. While these figures are certainly abysmal, not all hope is lost. Slowly but surely Notified Bodies are optimizing their review processes to continue to improve speed without compromising a robust review.

If you need assistance with EU MDR Transition or working through the certification process, contact EMMA International at 248-987-4497 or email info@emmainternational.com today!


[1] MedTech Europe (July 2022) Analyzing the availability of Medical Devices in 2022 in connection to the MDR implementation retrieved on 07/25/2022 from: https://www.medtecheurope.org/resource-library/medtech-europe-survey-report-analysing-the-availability-of-medical-devices-in-2022-in-connection-to-the-medical-device-regulation-mdr-implementation/

Madison Green

Madison Green

Director of Technical Operations - Mrs. Green serves as EMMA International’s Director of Technical Operations. She has experience in technical writing, nonconforming product management, issue evaluations, and implementing corrective and preventative actions in the pharmaceuticals and medical device industries. She has experience cross-functionally between R&D, lean manufacturing operations, and RA compliance. Mrs. Green also has academic and work experience with human health-risk engineering controls, physiological biophysics, and clinical research. Mrs. Green holds a Bachelor of Science in Biosystems Engineering with a concentration in Biomedical Engineering from Michigan State University. She is also a Certified Quality Auditor (CQA), and is currently pursuing her M.S. in Quality Management.

More Resources

Change Management And Control

Change Management And Control

One of the biggest and most important aspects of quality management is a system to monitor changes and how they impact the product. Change management is an approach for changing processes or products in a way which adheres to regulatory standards by ensuring stability and consistency throughout processes. It applies across all changes within a process and throughout an entire products life cycle.
Aseptic Technique and Gowning

Aseptic Technique and Gowning

One of the most common techniques to prevent contamination of products and reduce quality impacts in the pharmaceutical industry is called aseptic gowning. Humans are the biggest sources of microbial contamination in cleanroom environments and therefore proper gowning procedures are essential to ensuring product quality. Proper training, education, hygiene, qualification, and authorization must be put in place and be required for entry to all clean room environments...
Importance of Pharmaceutical GMP

Importance of Pharmaceutical GMP

Having high quality standards is vital to any organization but is even more essential in the pharmaceutical industry. Practices that are governed by these standards are commonly called Good Manufacturing Practices (GMP) and ensure consistent and controlled production of products. These practices govern all aspects and procedures within production and provide documented proof that procedures are consistently followed during the manufacturing processes every time products are made. They are designed to minimize risks throughout the manufacturing process that are not able to be eliminated in final product testing so that pharmaceuticals are safe for use...

Ready to learn more about working with us?

Pin It on Pinterest

Share This